(RTTNews) – Today’s Daily Dose brings you news about AstraZeneca pausing its phase 3 study of COVID-19 vaccine candidate, Albireo’s positive data from phase 3 trial of Odevixibat in progressive familial intrahepatic cholestasis, Corbus’ disappointing results from its phase 3 trial of Lenabasum in diffuse cutaneous systemic sclerosis, RedHill’s promising ‘in vitro’ data of COVID-19 drug candidate, Spero’s ADAPT-PO trial results and Pfizer’s equity investment in Trillium.
1. AstraZeneca Pauses COVID-19 Vaccine Trial
AstraZeneca PLC (AZN) has paused the phase III study of its COVID-19 vaccine candidate, AZD1222, following an adverse reaction in a trial participant, reports Stat News.
AZD1222, being developed by AstraZeneca and the University of Oxford researchers, is in phase III development in the U.S., UK, Brazil, and South Africa with additional trials planned to start in Japan and Russia.
The U.S. has recorded 6,326,696 active cases of COVID-19 and 189,639 deaths as of this